tric surgery are major advances in our country, thus standardization and high-quality practice can be achieved.Checklists can improve adherence to standardized procedures and minimize human error. We aimed to test if implementation of a checklist was feasible and effective in enhancing patient care in an emergency department handling internal medicine cases. We developed four critical event checklists and confronted volunteer teams with a series of four simulated emergency scenarios.  https://www.selleckchem.com/products/atezolizumab.html  In two scenarios, the teams were provided access to the crisis checklists in a randomized cross-over design. Simulated patient outcome plus statement of the underlying diagnosis defined the primary endpoint and adherence to key processes such as time to commence CPR represented the secondary endpoints. A questionnaire was used to capture participants' perception of clinical relevance and manageability of the checklists. Six teams of four volunteers completed a total of 24 crisis sequences. The primary endpoint was reached in 8 out of 12 sequences with and in 2 out of 12 sequences without a checklist (Odds ratio, 10; CI 1.11, 123.43; p = 0.03607, Fisher's exact test). Adherence to critical steps was significantly higher in all scenarios for which a checklist was available (performance score of 56.3% without checklist, 81.9% with checklist, p = 0.00284, linear regression model). All participants rated the checklist as useful and 22 of 24 participants would use the checklist in real life. Checklist use had no influence on CPR quality. The use of context-specific checklists showed a statistically significant influence on team performance and simulated patient outcome and contributed to adherence to standard clinical practices in emergency situations.
  Ultrasonographic estimation of gestational age is done routinely by using fetal biometric parameters, such as the biparietal diameter (BPD), femur length (FL), abdominal circumference (AC), and head circumference (HC). Gestational dating by ultrasound is reliable in the 1st trimester, but discrepancies increase to more than 3weeks in the 3rd trimester.
 
  To study the accuracy of gestational age estimation by the transcerebellar diameter (TCD) in the 3rd trimester of singleton pregnancies whose gestational age is known.
 
  A prospective study was carried out in the Department of Obstetrics and Gynecology at NDMC Medical College and Hindu Rao Hospital, Delhi, India, from October 2017 to May 2019 after obtaining clearance from the ethical committee. The study included 100 women aged 18-35years with singleton pregnancies in the 3rd trimester with a gestational age ≥ 28weeks; the women provided informed consent and filled in an F-form to rule out any sex determination of the baby. Only those women who had regular near-term pregnancy. Thus, the TCD was a reliable parameter for the estimation of gestational age within 6 days of near-term pregnancy along with routine biometry and an alternative parameter for the evaluation of gestational age when the LMP is not known.This paper will review neuroendocrine lesions of the thyroid and the differential diagnosis with the most significant such tumor of the thyroid, that is, medullary thyroid carcinoma. A brief overview of the understanding of this tumor's identification as a lesion of C cells and its familial and syndromic associations will be presented. Then, a discussion of the various mimics of medullary carcinoma will be given with an approach to the types of tests that can be done to arrive at a correct diagnostic conclusion. This review will focus on practical "tips" for the practicing pathologist.
  Fatigue is highly prevalent and burdensome in systemic lupus erythematosus (SLE). The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) is a patient-reported questionnaire that measures physical and mental fatigue and consequent impact on daily living. Qualitative evidence of content validity in SLE is limited. This study (GSK Study 209226) assessed the content validity of the FACIT-Fatigue for SLE and explored patients' experiences of SLE-related fatigue using qualitative methods.
 
  Fatigue-related themes were identified through semi-structured, hybrid cognitive debriefing and concept elicitation interviews and evaluated for concordance with the FACIT-Fatigue.
 
  Fatigue was experienced regularly by all participants (N = 15, 86.7% female) and was rated as the most bothersome symptom of SLE by 11/15 participants. All participants reported emotional impacts of fatigue, while 14/15 and 9/15 participants also reported impacts on social life and physical functioning, respectively. Most (12for measuring a common and debilitating symptom of this condition.
 Qualitative evaluation of the content validity of the FACIT-Fatigue supports it as an appropriate measure for assessing the impact of fatigue on daily living of patients with SLE. The tool is easily understood by patients and a valuable resource for measuring a common and debilitating symptom of this condition.
  We assessed patient-reported outcomes from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection (RCI; Acthar
  Gel) in patients with persistently active systemic lupus erythematosus (SLE) despite treatment with moderate-dose glucocorticoids.
 
  The trial enrolled adults with active SLE and moderate-to-severe rash and/or arthritis despite use ofstable glucocorticoids (7.5mg/day to 30mg/day prednisone equivalent), antimalarials, and nonsteroidal anti-inflammatory drugs for ≥ 4weeks and/or immunosuppressants for ≥ 8weeks before screening. Patients were randomly assigned to 80 U of RCI or placebo subcutaneously every other day through week 4, then twice weekly through week 24. Primary analyses evaluated the change from baseline to week 24 in the Lupus Quality of Life (QoL) and Work Productivity and Activity Impairment (WPAI)-Lupus questionnaires. Post hoc analyses stratified results by baseline disease activity (SLE Disease Activity Index-2000 [SLEDAI-2K] < 1ith standard SLE therapy.
 
  ClinicalTrials.gov identifier NCT02953821.
 ClinicalTrials.gov identifier NCT02953821.